Symptomatic Intracerebral Hemorrhage in Acute Ischemic Stroke After Thrombolysis With Intravenous Recombinant Tissue Plasminogen Activator
JAMA Neurol 81:1181-1185, Yaghi, S.,et al, 2014
Diagnosis and Management of Cerebral Venous Thrombosis: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association
Stroke 42:1158-1192, Saposnik,G.,et al, 2011
Stroke
Lancet 371:1612-1623, Donnan,G.A.,et al, 2008
Guidelines for the Early Management of Patients with Ischemic Stroke
Stroke 36:916-921, Adams,H.,et al, 2005
Guidelines for the Early Management of Patients with Ischemic Stroke
Stroke 34:1056-1083, Adams,H.P.,et al, 2003
Further Evolution Toward Effective Therapy for Acute Ischemic Stroke
JAMA 279:1298-1303, 13041998., Fisher,M.&Bogousslavsky,J., 1998
Brain SPECT with HMPAO & Safety of Thrombolytic Therapy in Acute Ischemic Stroke
Stroke 28:1830-1834, Alexandrov,A.V.,et al, 1997
Prospective Study of Endogenous Tissue Plasminogen Activator and Risk of Stroke
Lancet 343:940-943, Ridker,P.M.,et al, 1994
Stroke Complic Acute MI, A Meta-Analysis of Risk Modific by Antigoac & Thrombolytic Therapy
Arch Int Med 152:2020-2024, Viatkus,P.T.,et al, 1992
Tissue Plasminogen Activator Plus Glutamate Antagonist Improves Outcome after Embolic Stroke
Arch Neurol 48:1235-1238, Zivin,J.A.&Mazzarella,V., 1991
Current Medical & Surgical Therapy for Cerebrovascular Disease
NEJM 317:1505-1516, Grotta,J.C., 1987